FAQ on Quantum BioPharma Ltd.'s CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
Summary
What is Quantum BioPharma Ltd. announcing?
Quantum BioPharma Ltd. announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has signed an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS for an upcoming Phase 2 clinical trial in multiple sclerosis (MS).
What is Lucid-MS?
Lucid-MS is a patented, first-in-class, non-immunomodulatory neuroprotective compound that has shown the ability to prevent demyelination, a key factor in MS and other neurodegenerative diseases, and has enabled animals to regain mobility in preclinical studies.
Why is this agreement significant?
This agreement is a key step towards filing an Investigational New Drug application with the FDA for Lucid-21-302 in MS, potentially leading to a new treatment option for restoring mobility in people with MS.
What are the next steps for Quantum BioPharma Ltd.?
The next steps include proceeding with the Phase 2 clinical trial to evaluate Lucid-MS’s efficacy in restoring mobility in MS patients, based on promising preclinical results.
How does Lucid-MS work?
Lucid-MS works by preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis, as demonstrated in preclinical models, offering a novel approach to treating neurodegenerative diseases.
Where can I find more information about Quantum BioPharma Ltd.?
More information about Quantum BioPharma Ltd. and updates relating to QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
What other projects does Quantum BioPharma Ltd. have?
Quantum BioPharma Ltd. is also involved in developing treatments for metabolic and alcohol misuse disorders, and maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc.
What is the significance of the Phase 2 trial for Lucid-MS?
The Phase 2 trial is significant as it will evaluate Lucid-MS’s potential to restore mobility in people with MS, building on a decade of preclinical studies where the therapy showed promising results in animals.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 143799